1. Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
- Author
-
Vinita Akula, Lily Chen, Yusuf Acikgoz, Katherine Klein, Betul Gok Yavuz, Lokman Cevik, Tarik Demir, Ashish Manne, Ilyas Sahin, Ahmed Kaseb, and Elshad Hasanov
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC treatment is challenging; surgical resection is the primary curative treatment for early-stage disease, but recurrence rates are high. Immune checkpoint inhibitors (ICIs) are a promising neoadjuvant treatment that can reduce recurrence rates and mortality after surgery and achieve complete/partial responses. Clinical trials provide strong evidence for the efficacy and safety of ICI monotherapy for neoadjuvant HCC treatment.
- Published
- 2025
- Full Text
- View/download PDF